Related Experiment Video
Updated: Feb 27, 2026
07:40
Minimally Invasive Transverse Aortic Constriction in Mice
Published on: March 14, 2017
21.7K
Transcatheter aortic valve implantation: initial experience in Hong Kong
M Ky Lee1, S F Chui1, A Kc Chan1
1Department of Medicine, Queen Elizabeth Hospital, Jordan, Hong Kong.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi
|June 29, 2017
Summary
Transcatheter aortic valve implantation (TAVI) offers a promising alternative for severe aortic stenosis patients unsuitable for surgery. This study in Hong Kong showed TAVI improved valve area and function with acceptable safety outcomes.
Area of Science:
- Cardiology
- Interventional Cardiology
- Geriatric Cardiology
Background:
- Aortic stenosis is a prevalent valvular heart disease in aging populations.
- Severe symptomatic aortic stenosis poses a high risk of mortality.
- Surgical aortic-valve replacement is standard but often not feasible for elderly or comorbid patients.
Purpose of the Study:
- To evaluate the efficacy and safety of transcatheter aortic valve implantation (TAVI).
- To assess TAVI outcomes in the Hong Kong Chinese population with severe aortic stenosis.
Main Methods:
- Retrospective analysis of 56 patients undergoing TAVI from December 2010 to September 2015.
- Data collection included baseline characteristics, procedural details, and 1-year clinical outcomes.
- Focus on efficacy (valve area, NYHA class) and safety (complications, mortality).
Main Results:
- Significant improvement in mean aortic valve area (0.70 to 1.94 cm²).
- 92% of patients improved by at least one NYHA functional class.
- Low rates of stroke (1.8%) and hospital mortality (1.8%); 1-year all-cause mortality was 12.5%.
Conclusions:
- TAVI is a viable alternative for high-risk or inoperable patients with severe aortic stenosis.
- The procedure demonstrated promising efficacy and safety in this Hong Kong cohort.
- Outcomes are comparable to major international clinical trials.
